跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PROTAC-6
首页
药物
PROTAC-6
PROTAC-6
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
COMPOUND CAPABLE OF DEGRADING EPIDERMAL GROWTH FACTOR RECEPTOR, AND USE THEREOF
WO 2025073251 A1
申请人: PRIMARY SUZHOU BIOTECHNOLOGY CO LTD
优先权: 2023
CN
WO
2 件公开
COMPOUND BINDING TO CRBN PROTEIN AND DEGRADATION AGENT OF PROTEIN
WO 2025082069 A1
申请人: OCEAN UNIV CHINA
优先权: 2023
CN
WO
2 件公开
Chimera for specifically degrading tau protein, encoding gene of chimera and application of chimera and encoding gene
CN 111518215 A
申请人: UNIV HUAZHONG SCIENCE TECH
优先权: 2019
CN
蛋白水解靶向嵌合体、提高其口服生物利用度的前药分子及应用
CN 111909155 B
申请人: 东莞理工学院
优先权: 2020
CN
一种靶向DDX24蛋白的水解靶向嵌合体及其应用
CN 114478797 B
申请人: 中山大学附属第五医院
优先权: 2021
CN
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING BTK DEGRADER AND BCL-6 DEGRADER
WO 2024228505 A1
申请人: UNIV INJE IND ACAD COOP FOUND
优先权: 2023
WO
2, 6-piperidinedione derivative as well as preparation and application thereof
CN 116655595 A
申请人: INST MILITARY MEDICINE ACADEMY MILITARY SCIENCES PLA
优先权: 2023
CN
3-[3-amino-6-(2-hydroxyphenyl) pyridazin-4-yl]-3, 8-diazabicyclo [3.2. 1] octane derivatives as SMARCA2 degrading PROTAC for treatment of cancer
CN 121285556 A
申请人: ASTRAZENECA SWEDEN AB
优先权: 2023
CN
PROTACs compound for double targeting degradation of estrogen receptor and human histone deacetylase 6 and application of PROTACs compound
CN 117362383 A
申请人: UNIV WUHAN
优先权: 2023
CN
一种可实时监测ERα蛋白降解的近红外荧光诊疗探针及其制备方法和应用
CN 117736261 B
申请人: 武昌理工学院
优先权: 2023
CN
第 1 / 2 页
上一页
下一页
药物
反馈